Skip to main content

Determining the Effectiveness of Addition of Drug Teneligliptin to Metformin, Glimepiride, Pioglitazone Combination in Type II Diabetic Patients | Chapter 06 | New Horizons in Medicine and Medical Research Vol. 1

 Diabetes is a widespread chronic disease that has spread to epidemic proportions in almost every developed and developing country. Diabetes is the leading cause of death in the world, affecting about 400 million people.

Aims and Objectives: To investigate the efficacy of combining Teneligliptin with Metformin, Glimepiride, and Pioglitazone in type 2 diabetic patients.

Methodology: This was a one-year cross-sectional study on type II diabetic patients conducted in the Department of Medicine at a tertiary health care centre from January 2017 to January 2018. Out of all type II diabetes patients, 40 were randomly selected for hypoglycemic therapy with the medications Metformin, Glimepiride, and Pioglitazone. Of these, 20 were continued on the prior treatment (Group B), while the remaining 20 were given the extra drug Teneligliptin (Group A). The statistical analysis was carried out using the SPSS 19 version of software and included an unpaired t-test and a chi-square test.

The average age in both groups was comparable, i.e. 36.78 6.74 and 38.92 5.87 (p>0.05,t=1.24,df=38), the sex ration was also comparable (p>0.43, X2 =0.43,df=1), and the HbA1C was comparable at 1st Wk. 10 4.56 - 9.87 3.42 (p>0.05, t = 1.023,df=38) and 4th Wk. 8

Conclusion: Our findings show that Teneligliptin addiction considerably lowered HbA1C levels at the end of the fourth week, making it superior to the standard Metformin, Glimepiride, and Pioglitazone alone combo treatment.

Author(S) Details


Dilip Pandurang Patil
Department of Medicine, Krishna Institute of Medical Sciences, Deemed to be University, Karad, Maharashtra, India.

View Book:- https://stm.bookpi.org/NHMMR-V1/article/view/6171


Comments